Genmab A/S (OTCMKTS:GNMSF – Get Free Report) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $261.40 and traded as low as $220.42. Genmab A/S shares last traded at $231.17, with a volume of 366 shares.
Genmab A/S Stock Up 2.4 %
The business’s 50 day moving average price is $242.98 and its 200-day moving average price is $261.40.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.13 earnings per share for the quarter. The firm had revenue of $779.50 million during the quarter. Genmab A/S had a return on equity of 20.60% and a net margin of 29.06%.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
- Five stocks we like better than Genmab A/S
- Canada Bond Market Holiday: How to Invest and Trade
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- Canadian Penny Stocks: Can They Make You Rich?
- Breakout Alert: Qualcomm Just Hit The Rally Button
- The Role Economic Reports Play in a Successful Investment Strategy
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
